KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 103 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,423,502 | +10.2% | 459,346 | +3.0% | 0.00% | – |
| Q2 2023 | $4,015,575 | +21.9% | 446,175 | +6.4% | 0.00% | – |
| Q1 2023 | $3,295,391 | -39.7% | 419,261 | -48.1% | 0.00% | – |
| Q4 2022 | $5,461,540 | -10.8% | 807,920 | +91.5% | 0.00% | – |
| Q3 2022 | $6,121,000 | +51.6% | 421,819 | +2.8% | 0.00% | – |
| Q2 2022 | $4,037,000 | -70.8% | 410,252 | -56.3% | 0.00% | -100.0% |
| Q1 2022 | $13,839,000 | -0.6% | 938,867 | -10.8% | 0.00% | 0.0% |
| Q4 2021 | $13,918,000 | -23.6% | 1,051,976 | +0.8% | 0.00% | 0.0% |
| Q3 2021 | $18,215,000 | -45.7% | 1,043,828 | -25.5% | 0.00% | -50.0% |
| Q2 2021 | $33,556,000 | +120.8% | 1,400,501 | +136.8% | 0.00% | +100.0% |
| Q1 2021 | $15,195,000 | +198.9% | 591,472 | +121.0% | 0.00% | – |
| Q4 2020 | $5,083,000 | +54.9% | 267,654 | +2.7% | 0.00% | – |
| Q3 2020 | $3,281,000 | +7.7% | 260,565 | +3.5% | 0.00% | – |
| Q2 2020 | $3,046,000 | +62.5% | 251,770 | +2.8% | 0.00% | – |
| Q1 2020 | $1,874,000 | -54.6% | 245,001 | +5.6% | 0.00% | – |
| Q4 2019 | $4,131,000 | +56.1% | 231,941 | +1.7% | 0.00% | – |
| Q3 2019 | $2,647,000 | -40.5% | 228,151 | +13.6% | 0.00% | – |
| Q2 2019 | $4,448,000 | +1715.5% | 200,826 | +2242.0% | 0.00% | – |
| Q1 2019 | $245,000 | – | 8,575 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |